Dr. Bedrosian joined Ultragenyx in January 2018 as Chief Medical Officer and Executive Vice President. In this role, she provides strategic leadership to the clinical development and translational research programs, and oversees global development functions including: Medical, Clinical, Development Operations, Regulatory, Biometrics/CORE, Drug Safety/Pharmacovigilance, and Patient Advocacy and Engagement.
Prior to joining Ultragenyx, Dr. Bedrosian served nearly a decade as Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals, Inc. Prior to Alexion, Dr. Bedrosian spent more than five years as the Chief Medical Officer for ARIAD Pharmaceuticals, Inc., and earlier she served in the Clinical Research and Development Department of Genetics Institute, Inc. (acquired by Wyeth, now part of Pfizer). Previously, Dr. Bedrosian was an Assistant Professor of Medicine at Duke University Medical Center and a member of the Duke Comprehensive Cancer Center, where she completed her residency in internal medicine and a fellowship in hematology and medical oncology.
Dr. Bedrosian serves on the Board of Directors of Rhythm Pharmaceuticals and Crinetics Pharmaceuticals.
Dr. Bedrosian earned an A.B., magna cum laude, in honors chemistry from Harvard University, an M.D. from Harvard Medical School, and an M.S. in biophysics from the Massachusetts Institute of Technology (MIT). She currently serves as a member of the MIT Corporation Visiting Committee for the Department of Biology.
What is Camille L. Bedrosian's net worth?
The estimated net worth of Camille L. Bedrosian is at least $6.36 million as of September 30th, 2024. Dr. Bedrosian owns 143,801 shares of Ultragenyx Pharmaceutical stock worth more than $6,358,880 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Bedrosian may own. Learn More about Camille L. Bedrosian's net worth.
How do I contact Camille L. Bedrosian?
Has Camille L. Bedrosian been buying or selling shares of Ultragenyx Pharmaceutical?
Camille L. Bedrosian has not been actively trading shares of Ultragenyx Pharmaceutical within the last three months. Most recently, Camille L. Bedrosian sold 3,881 shares of the business's stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $45.25, for a transaction totalling $175,615.25. Following the completion of the sale, the executive vice president now directly owns 46,720 shares of the company's stock, valued at $2,114,080. Learn More on Camille L. Bedrosian's trading history.
Who are Ultragenyx Pharmaceutical's active insiders?
Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Eric Crombez (Chief Medical Officer and EVP), Mardi Dier (CFO), Matthew Fust (Director), Erik Harris (EVP), Howard Horn (CFO and EVP, Corporate Strategy), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?
During the last twelve months, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 100,072 shares worth more than $5,115,593.08. The most recent insider tranaction occured on December, 10th when CEO Emil D Kakkis sold 8,273 shares worth more than $413,650.00. Insiders at Ultragenyx Pharmaceutical own 5.8% of the company.
Learn More about insider trades at Ultragenyx Pharmaceutical. Information on this page was last updated on 12/10/2024.
